Last reviewed · How we verify
Bevacizumab or Bevacizumab biosimilar — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Bevacizumab or Bevacizumab biosimilar (Bevacizumab or Bevacizumab biosimilar) — BeiGene.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bevacizumab or Bevacizumab biosimilar TARGET | Bevacizumab or Bevacizumab biosimilar | BeiGene | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bevacizumab or Bevacizumab biosimilar CI watch — RSS
- Bevacizumab or Bevacizumab biosimilar CI watch — Atom
- Bevacizumab or Bevacizumab biosimilar CI watch — JSON
- Bevacizumab or Bevacizumab biosimilar alone — RSS
Cite this brief
Drug Landscape (2026). Bevacizumab or Bevacizumab biosimilar — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-or-bevacizumab-biosimilar. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab